Skip to content
Contact Us
iStock-1421515036 (2) iStock-1421515036 (2)

Gene Expression Profiling of Biopsies

Gene expression profiling of tumor biopsies and liquid biopsies can provide insight into inflammation and overall immune status
Profiling of biopsies by gene expression can serve as a tool for screening tumors that may respond to treatments such as checkpoint inhibitors, for evaluating therapeutic efficacy, for illuminating mechanism of action, and for a range of other applications

Comprehensive and quantitative gene expression profiling

Precision offers gene expression profiling and transcriptomics assays to monitor immune status using next generation sequencing (NGS), NanoString, qPCR, and Droplet Digital™ PCR (ddPCR) technologies. For sample types and needs other than immune profiling of biopsies, Precision also offers a full suite of genomics applications.

Our services are designed to meet your project objectives, whether through pre-existing panels or a customized assay.

Illumina and Thermo Fisher NGS Sequencers

We use both Illumina and Thermo Fisher for next-gen sequencing. Also, RNA-seq studies are done using Illumina, including the AmpliSeq for Illumina Immune Response Panel.

NanoString nCounter®

For highly multiplexed, quantitative gene expression studies, we use the NanoString nCounter® platform. This system directly detects RNA, avoiding the potential for introduced bias with approaches that rely on PCR-based amplification.

We can use NanoString’s immuno-oncology and immunology panels or create a custom panel for your study.

QuantStudio™ 12K flex real-time PCR system

For cost-effective, multiplexed gene expression profiling of many samples in parallel, we offer analyses using OpenArray plates on the QuantStudio 12K Flex qPCR platform.

QX200™ ddPCR™

Digital PCR is appropriate when highly sensitive analyses and absolute quantification is needed. Precision utilizes the Bio-Rad QX200 ddPCR System.

Agena MassARRAY®

High-throughput solution for genotyping, somatic mutation detection, DNA methylation analysis, and gene expression regulation analysis. Precision for Medicine offers MassARRAY® assays either as an individual service or as part of a comprehensive therapeutic development package, which includes biomarker assays and clinical trials.

Precision also provides research-ready biospecimens

In addition to services, Precision has biospecimens ready for genomic analysis, as well as specimens pre-characterized via NGS.

FFPE Tissues Explore NGS Characterized Biospecimens Explore Tissue Microarrays Explore

Explore the Precision blog

Read our blog to gain more insights and discover work that Precision has supported.

Explore our blog
Read: Progress in Gastrointestinal Oncology: 5 Key Insights from ASCO GI Progress in Gastrointestinal Oncology: 5 Key Insights from ASCO GI

Progress in Gastrointestinal Oncology: 5 Key Insights from ASCO GI

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=178509987433, hs_child_table_id=0, hs_updated_at=1728330014032, hs_published_at=1739807653319, description=Ivan Barrera, MD is a fellowship-trained expert in Research GI Oncology with over 15 years of clinical research experience across various healthcare systems and facilities. He is a methodical and strategic key player in interdisciplinary drug development teams, specializing in medical monitoring. Dr. Barrera has extensive experience in solid tumors, particularly Gastrointestinal Oncology, including Neuroendocrine Tumors, and has worked on FIH and Phase I-IV studies. His industry clinical development experience spans small molecules, antibodies, vaccines, cytokines, oncolytic viruses, radiopharmaceuticals, and cellular therapies., avatar=Image{width=685,height=649,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Ivan%20Barrera.jpg',altText='Ivan Barrera',fileId=180445483936}, lastname=Barrera, hs_initial_published_at=1726512636738, hs_created_by_user_id=26433386, hs_created_at=1726500269983, hs_is_edited=false, hs_deleted_at=0, name=Ivan, job=Senior Medical Director, slug=ivan-barrera, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Ivan Barrera avatar

    Ivan Barrera
Discover
Read: Case Study Phase 3 NSCLC: Site Relationships Streamline Feasibility Case Study Phase 3 NSCLC: Site Relationships Streamline Feasibility

Clinical Trials

Case Study Phase 3 NSCLC: Site Relationships Streamline Feasibility

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=185838258545, hs_child_table_id=0, hs_updated_at=1738849388884, hs_published_at=1739807653319, description=Anna Rodecki is a results driven leader with 24 years of experience in clinical research across the pharmaceutical, device, and biotech industries. She has played a pivotal role in shaping clinical development plans on both Sponsor and CRO, successfully supporting First- In-Human (FIH) – Phase IV trials successfully across various therapeutics areas. Anan thrives on building strong, collaborative teams fostering innovation. Her expertise spans strategic planning, risk management, inspection readiness and cross-functional leadership – always with a focus on improving patient outcomes and advancing the future of medicine., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Anna%20Rodecki.png',altText='Anna Rodecki',fileId=185842773784}, lastname=Rodecki, hs_initial_published_at=1738849393727, hs_created_by_user_id=26433386, hs_created_at=1738849349748, hs_is_edited=false, hs_deleted_at=0, name=Anna, job=Director, Project Management, slug=anna-rodecki, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Anna Rodecki avatar

    Anna Rodecki
Discover
Read: Source Data Verification Types, Trends, and Tips Source Data Verification Types, Trends, and Tips

Clinical Trials

Source Data Verification Types, Trends, and Tips

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=183222587782, hs_child_table_id=0, hs_updated_at=1732630460690, hs_published_at=1739807653319, description=Jelena Alexander brings 18 years of industry experience across the CRO, biotech and R&D arenas, with the last eight years focused on clinical operations oversight and aligning resources with project needs. Prior to transitioning to clinical research, Jelena obtained a Master’s degree in infectious disease and immunology, specializing in the development of cross-reactive and neutralizing monoclonal antibodies to foot-and-moth disease virus. Jelena is a collaborative leader recognized for fostering relationships with stakeholders to embed sustainable workflow processes and for delivering high quality outputs to ensure business needs are accomplished on time and within budget. Jelena’s expertise extends to evaluating and assessing clinical proposals, with a focus on monitoring strategies, and operational feasibility. In this role, Jelena leverages operational and leadership expertise to deliver high-quality, client-focused solutions while enhancing efficiency and sustainability in proposal strategies. Jelena is devoted to driving innovation, mentoring teams, and achieving results through adaptability and commitment to quality., avatar=Image{width=800,height=800,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Jelena%20Alexander.jpg',altText='Jelena Alexander',fileId=183228271491}, lastname=Alexander, hs_initial_published_at=1732630470588, hs_created_by_user_id=26433386, hs_created_at=1732630317363, hs_is_edited=false, hs_deleted_at=0, name=Jelena, job=Senior Manager, Global Clinical Monitoring, slug=jelena-alexander, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Jelena Alexander avatar

    Jelena Alexander
Discover